1. Home
  2. PAYS vs LCTX Comparison

PAYS vs LCTX Comparison

Compare PAYS & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PAYS
  • LCTX
  • Stock Information
  • Founded
  • PAYS 2001
  • LCTX 1990
  • Country
  • PAYS United States
  • LCTX United States
  • Employees
  • PAYS N/A
  • LCTX N/A
  • Industry
  • PAYS Business Services
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PAYS Consumer Discretionary
  • LCTX Health Care
  • Exchange
  • PAYS Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • PAYS 303.3M
  • LCTX 274.0M
  • IPO Year
  • PAYS 1998
  • LCTX N/A
  • Fundamental
  • Price
  • PAYS $5.23
  • LCTX $1.82
  • Analyst Decision
  • PAYS Strong Buy
  • LCTX Strong Buy
  • Analyst Count
  • PAYS 4
  • LCTX 4
  • Target Price
  • PAYS $8.06
  • LCTX $4.25
  • AVG Volume (30 Days)
  • PAYS 354.9K
  • LCTX 1.9M
  • Earning Date
  • PAYS 11-12-2025
  • LCTX 11-06-2025
  • Dividend Yield
  • PAYS N/A
  • LCTX N/A
  • EPS Growth
  • PAYS N/A
  • LCTX N/A
  • EPS
  • PAYS 0.12
  • LCTX N/A
  • Revenue
  • PAYS $68,539,381.00
  • LCTX $10,914,000.00
  • Revenue This Year
  • PAYS $35.44
  • LCTX N/A
  • Revenue Next Year
  • PAYS $21.93
  • LCTX $176.00
  • P/E Ratio
  • PAYS $43.55
  • LCTX N/A
  • Revenue Growth
  • PAYS 27.84
  • LCTX 76.43
  • 52 Week Low
  • PAYS $1.80
  • LCTX $0.37
  • 52 Week High
  • PAYS $8.88
  • LCTX $2.09
  • Technical
  • Relative Strength Index (RSI)
  • PAYS 41.38
  • LCTX 58.24
  • Support Level
  • PAYS $5.06
  • LCTX $1.66
  • Resistance Level
  • PAYS $5.33
  • LCTX $2.09
  • Average True Range (ATR)
  • PAYS 0.22
  • LCTX 0.12
  • MACD
  • PAYS -0.05
  • LCTX 0.00
  • Stochastic Oscillator
  • PAYS 15.87
  • LCTX 51.79

About PAYS Paysign Inc.

PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: